Tamoxifen Research & Listing Availability

How it works

Tamoxifen is a triphenylethylene SERM. The parent molecule has modest direct activity at the estrogen receptor; the dominant pharmacologic effect comes from its two main metabolites — 4-hydroxytamoxifen and N-desmethyl-4-hydroxytamoxifen (endoxifen) — both produced by hepatic CYP2D6.[3] These metabolites bind the estrogen receptor (both ERα and ERβ) and act as competitive antagonists, blocking estradiol binding. The "selective" character of SERMs reflects tissue-specific differences in co-activator and co-repressor recruitment to the receptor: in breast tissue, tamoxifen-bound ER recruits predominantly co-repressors and acts as a functional antagonist (blocking proliferation); in endometrial, bone, and hepatic tissue, tamoxifen-bound ER recruits more co-activators and acts as a partial agonist. The clinical implications are direct: tamoxifen blocks ER-driven breast-cancer proliferation, preserves bone density in postmenopausal women, has mild beneficial effects on lipid profiles, but carries a small increased risk of endometrial hyperplasia, endometrial cancer, and thromboembolic events. CYP2D6 metabolism creates pharmacogenomic variability — poor metabolisers (carriers of low-activity CYP2D6 alleles) produce less endoxifen and may have reduced clinical benefit.

Active research areas

• Adjuvant therapy of ER-positive early breast cancer
  The largest evidence base in oncology. NSABP B-14 established the recurrence benefit in node-negative ER-positive disease;[4] the EBCTCG meta-analyses confirmed that 5 years of adjuvant tamoxifen reduces breast-cancer recurrence by approximately 50% and breast-cancer mortality by approximately 30%, with the effect persisting more than 15 years after treatment ends.[5] ATLAS established that 10 years of treatment is superior to 5 years for high-risk disease.[6]
• Breast-cancer risk reduction (NSABP P-1, IBIS-I)
  NSABP P-1 reported a 49% reduction in invasive breast cancer incidence in high-risk women on 5 years of tamoxifen versus placebo;[7] IBIS-I confirmed the effect in a European cohort. The FDA approved tamoxifen for risk reduction in 1998 — making it the first agent ever approved for primary cancer prevention.
• Metastatic ER-positive breast cancer
  Tamoxifen remains a treatment option in metastatic ER-positive disease, particularly in premenopausal women where aromatase inhibitors require ovarian suppression. The arrival of CDK4/6 inhibitors and aromatase-inhibitor combinations has reduced its first-line role but it retains a place in the treatment algorithm.
• Gynecomastia (off-label, including PCT use)
  Off-label use for pubertal and adult gynecomastia, including for gynecomastia precipitated by anabolic-steroid use, is widespread. The pediatric evidence supports efficacy (Lawrence 2004),[8] and the mechanism (blocking estrogen-driven breast-tissue proliferation) is the same as in the approved oncology indication. Long-term safety in non-cancer male populations is not characterised by Phase 3 trials.
• Anabolic-steroid post-cycle therapy (PCT, off-label)
  A large off-label use is as part of PCT after anabolic-steroid cycles, where tamoxifen's estrogen-receptor blocking activity at the hypothalamus is used to restart HPG-axis function (analogous to the clomiphene/enclomiphene PCT use) and to mitigate gynecomastia from aromatised steroids during and after cycles. This use is anecdotal — no controlled trial has tested tamoxifen specifically for PCT — and the safety profile in young, healthy, recreationally-dosed users is not characterised.